Skip to main content
SpringerLink
Log in

Lipid Peroxidation Products in the Blood Plasma of Patients with Parkinson’s Disease as Possible Biomarkers of Different Stages of the Disease

  • CLINICAL NEUROCHEMISTRY
  • Published:
Neurochemical Journal Aims and scope Submit manuscript

Abstract—Oxidative stress (OS) plays a significant role in the pathogenesis of Parkinson’s disease (PD) and is accompanied by the development of free radical reactions of lipid peroxidation. The growth of highly reactive products of oxidative metabolism of polyunsaturated fatty acids (PUFAs) leads to dysfunction and the subsequent death of dopaminergic neurons and contributes to the emergence and progression of PD. This paper assesses the prognostic significance of lipid peroxidation (LPO) products determined in the blood of patients with PD as possible biomarkers of various stages of the disease. The content of lipid hydroperoxides (LH), malondialdehyde (MDA), and 4-hydroxynonenals (4-HNE) was determined in the peripheral blood of 240 patients at stages 1–4 of the disease according to the Hoehn and Yahr scale. For all examined patients, regardless of the stage of the disease (stages 2–4), an increase in the level of lipid hydroperoxides by 20% was observed, on average. Elevated levels of MDA were registered in patients with a higher disease severity who were at the advanced stages of the disease (stages 3 and 4). For patients at stages 1 and 2 of the disease the content of MDA remained within normal levels. The content of 4-HNE increased in patients at stages 2, 3, and 4 of the disease proportionally to the severity of the disease. The most pronounced increase in the content of 4-HNE was detected in patients at the advanced stages of the disease (stages 3 and 4). In patients at the second, earlier stage of the disease, the value of this parameter was 34% lower than that in patients at the advanced stages. In patients at the first stage of the disease, all measured parameters of LPO were comparable to control values and therefore could not play a significant diagnostic biomarker role. An important aspect of this study is that some LPO markers (LH and 4-HNE) are associated with both early and late stages of the disease, while the content of MDA increased at the advanced stages. Therefore, MDA and 4-HNE may have a high prognostic value, reflecting the severity of the disease. The most sensitive and specific indicator of LPO is 4-HNE, since its content increases proportionally to the severity of the disease (stage 2 < stage 3 < stage 4). The results we obtained are important for the development of complex neuroprotective approaches to the treatment of this disease, which can prevent the selective death of nervous tissue in PD and delay the development of the neurodegenerative process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

REFERENCES

  1. Jenner, P., Ann. Neurol., 2003, vol. 53, no. Suppl. 3, pp. S26–S36.

  2. Segura-Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., and Zucca, F.A., J. Neurochem., 2014, vol. 129, no. 6, pp. 898–915.

    Article  CAS  Google Scholar 

  3. Titova, N.V. and Chauduri, K.R., Ann. Klinich. i Eksperim. Nevrol, 2017, vol. 11, no. 4, pp. 5–18.

  4. Montine, K.S., Quinn, J.F., Zhang, J., Fessel, J.P., Roberts, L.J. II, Morrow, J.D., and Montine, T.J., Chem. Phys. Lipids, 2004, vol. 128, nos. 1–2, pp. 117–124.

    Article  CAS  Google Scholar 

  5. Anderson, G. and Maes, M., Mol. Neurobiol, 2014, vol. 49, no. 2, pp. 771–783.

    Article  CAS  Google Scholar 

  6. Kato, Y. and Osawa, T., Arch. Biochem. Biophys., 2010, vol. 501, no. 2, pp. 182–187.

    Article  CAS  Google Scholar 

  7. Esterbauer, H., Schaur, J.R., and Zollner, H., Free Radical Biol. Med., 1991, vol. 11, no. 1, pp. 81–128.

    Article  CAS  Google Scholar 

  8. Mattson, M.P., Trends Neurosci., 1998, vol. 20, no. 2, pp. 53–57.

    Article  Google Scholar 

  9. Liu, W., Kato, M., Akhand, A.A., Hayakawa, A., Suzuki, H., Miyata, T., Kurokawa, K., Hotta, Y., Ishiakawa, N., and Nakashima, I., Journal Cell Science, 2000, vol. 113, pt. 4, pp. 635–641.

  10. Ji, C., Amarnath, V., Pietenpol, J.A., and Marnett, L.J., Chem. Res. Toxicol., 2001, vol. 14, no. 8, pp. 1090–1096.

    Article  CAS  Google Scholar 

  11. Castellani, R.J., Perry, G., Siedlak, S.L., Nunomura, A., Shimohama, S., Zhang, J., Montine, T., Sayre, L.M., and Smith, M.A., Neurosci. Let., 2002, vol. 319, no. 1, pp. 25–28.

    Article  CAS  Google Scholar 

  12. Shamoto-Nagai, M., Hisaka, S., Naoi, M., and Maruyama, W., J. Clin. Biochem. Nutr., 2018, vol. 62, no. 3, pp. 207–212.

    Article  CAS  Google Scholar 

  13. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E.R., and Mizuno, Y., Proc. Natl. Acad. Sci. USA, 1996, vol. 93, no. 7, pp. 2696–2701.

    Article  CAS  Google Scholar 

  14. Dexter, D.T., Holley, A.E., Flitter, W.D., Slater, T.F., Wells, F.R., Daniel, S.E., Lees, A.J., Jenner, P., and Marsden, C.D., Mov. Disord., 1994, vol. 9, no. 1, pp. 92–97.

    Article  CAS  Google Scholar 

  15. Munch, G., Gerlach, M., Sian, J., Wong, A., and Riederer, P., Ann. Neurol., 1998, vol. 44, no. 3, suppl. 1, pp. S85—S88.

    Article  CAS  Google Scholar 

  16. Selley, M.L., Free Radical Biology & Medicine, 1998, vol. 25, no. 2, pp. 169–174.

    Article  CAS  Google Scholar 

  17. Buhmann, C., Arlt, S., Kontush, A., Moller-Bertram, T., Sperber, S., Oechsner, M., Stuerenburg, H.J., and Beisiegel, U., Neurobiology of Disease, 2004, vol. 15, no. 1, pp. 160– 170.

    Article  CAS  Google Scholar 

  18. Younes-Mhenni, S., Frih-Ayed, M., Kerkeni, A., Bost, M., and Chazot, G., Eur. Neurol., 2007, vol. 58, no. 2, pp. 78–83.

    Article  CAS  Google Scholar 

  19. Sharma, A., Kaur, P., Kumar, B., Prabhakar, S., and Gill, K.D., Parkinsonism Relat. Disord., 2008, vol. 14, no. 1, pp. 52–57.

    Article  Google Scholar 

  20. Nikam, S., Nikam, P., Ahaley, S.K., and Sontakke, A.V., Indian J. Clin. Biochem., 2009, vol. 24, no. 1, pp. 98–101.

    Article  CAS  Google Scholar 

  21. Chen, C.M., Liu, J.L., Wu, Y.R., Chen, Y.C., Cheng, H.S., Cheng, M.L., and Chiu, D.T.Y., Neurobiology of Disease, 2009, vol. 33, no. 3, pp. 429–435.

    Article  CAS  Google Scholar 

  22. Molina, J.A., Jimenez-Jimenez, F.J., Fernandez-Calle, P., Lalinde, L., Tenias, J.M., and Pondal, M., Neurosci. Let., 1992, vol. 136, no. 2, pp. 137–140.

    Article  CAS  Google Scholar 

  23. Ahlskog, J.E., Uitti, R.J., Low, P.A., Tyce, G.M., Nickander, K.K., Petersen, R.C., and Kokmen, E., Mov. Disord., 1995, vol. 10, no. 5, pp. 566–573.

    Article  CAS  Google Scholar 

  24. Çubukçu, H.C., Yurtdaş, M., Durak, Z.E., Aytaç, B., Güneş, H.N., Çokal, B.G., Yoldaş, T.K., and Durak, İ., Neurol. Sci., 2016, vol. 37, no. 11, pp. 1793–1798.

    Article  Google Scholar 

  25. Shukla, R., Rajani, M., Srivastava, N., Barthwal, M.K., and Dikshit, M., Int. J. Neurosci., 2006, vol. 116, no. 12, pp. 1391–1402.

    Article  CAS  Google Scholar 

  26. de Farias, C.C., Maes, M., Bonifacio, K.L., Bortolasci, C.C., de Souza, NogueiraA., Brinholi, F.F., Matsumoto, A.K., do Nascimento, M.A., de Melo, L.B., Nixdorf, S.L., Lavado, E.L., Moreira, E.G., and Barbosa, D.S, Neuroscience Let., 2016, vol. 617, pp. 66–71.

    Article  Google Scholar 

  27. Fedorova, T.N., Logvinenko, A.A., Poleshchuk, V.V., and Illarioshkin, S.N., Neurochem J., 2017, vol. 11, no. 4, pp. 340–345.

    Article  CAS  Google Scholar 

  28. Barnham, K.J., Masters, C.L., and Bush, A.I., Nat. Rev. Drug. Discov, 2004, vol. 3, no. 3, pp. 205–214.

    Article  CAS  Google Scholar 

  29. Chinta, S.J. and Andersen, J.K., Biochim. Biophys. Acta, 2008, vol. 1780, no. 11, pp. 1362–1367.

    Article  CAS  Google Scholar 

  30. Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropoulos, H., Trojanowski, J.Q., and Lee, V.M., Science, 2000, vol. 290, no. 5493, pp. 985 – 989.

    Article  CAS  Google Scholar 

  31. Dawson, T.M. and Dawson, V.L., Science, 2003, vol. 302, no. 5646, pp. 819–822.

    Article  CAS  Google Scholar 

  32. Näsström, T., Fagerqvist, T., Barbu, M., Karlsson, M., Nikolajeff, F., Kasrayan, A., Ekberg, M., Lannfelt, L., Ingelsson, M., and Bergström, J., Free Radic. Biol. Med., 2011, vol. 50, no. 3, pp. 428–437.

    Article  Google Scholar 

  33. Zhang, S., Eitan, E., and Mattson, M.P., J. Neurochem., 2017, vol. 140, no. 6, pp. 941–995.

    Article  CAS  Google Scholar 

  34. Serra, J.A., Dominguez, R.O., and De Lustig, E.S., J. Neural. Transm., 2001, vol. 108, no. 10, pp. 1135–1148.

    Article  CAS  Google Scholar 

  35. Sanyal, J., Bandyopadhyay, S.K., Banerjee, T.K., Mukherjee, S.C., Chakraborty, D.P., Ray, B.C., and Rao, V.R., Eur. Rev. Med. Pharmacol. Sci., 2009, vol. 13, no. 2, pp. 129–132.

    CAS  PubMed  Google Scholar 

Download references

Funding

No external funding was received.

Author information

Authors and Affiliations

  1. Research Center of Neurology, Volokolamshoe shosse 80, 125367, Moscow, Russia

    T. N. Fedorova, A. A. Logvinenko, V. V. Poleshchuk, O. A. Muzychuk, A. A. Shabalina & S. N. Illarioshkin

Authors
  1. T. N. Fedorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. A. Logvinenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. V. Poleshchuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O. A. Muzychuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. A. Shabalina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. N. Illarioshkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. N. Fedorova.

Ethics declarations

Conflict of interest. The authors declare that they have no conflict of interest.

Informed consent. Informed consent was obtained from all individual participants included in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fedorova, T.N., Logvinenko, A.A., Poleshchuk, V.V. et al. Lipid Peroxidation Products in the Blood Plasma of Patients with Parkinson’s Disease as Possible Biomarkers of Different Stages of the Disease. Neurochem. J. 13, 391–395 (2019). https://doi.org/10.1134/S1819712419040020

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1819712419040020

Keywords:

Search

Navigation